MedPage Today -- Adding the signaling molecule interleukin-2 to standard HIV therapy has no effect on the risk of death or opportunistic disease, two major clinical trials have concluded.
MedPage Today -- Adding the signaling molecule interleukin-2 to standard HIV therapy has no effect on the risk of death or opportunistic disease, two major clinical trials have concluded.
